Ainos vs Virax Biolabs
AIMD and VRAX side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AIMD and VRAX compare
Virax Biolabs grew revenue faster over the last twelve months (96.2% versus −87.7% for Ainos).
Virax Biolabs keeps more of each dollar of sales as profit, with a net margin of −40439% compared with −106283% at Ainos.
Virax Biolabs scores higher on the StockData Score (9 against 1 for Ainos), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AIMD | VRAX |
|---|---|---|
| Size and price | ||
| Market cap | $7.8M | – |
| Share price | $1.06 | $0.668 |
| Change, 1 year | −66.0% | −94.3% |
| Change, 5 years | −99.6% | – |
| Beta (5Y) | 2.68 | 1.61 |
| Employees | 41 | – |
| StockData Score | ||
| Total score | 1 | 9 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 3 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 576× | – |
| P/B | 2.4× | – |
| FCF yield | −57.4% | – |
| Growth | ||
| Revenue growth (TTM) | −87.7% | 96.2% (better) |
| Revenue growth, 5Y average | 49.6% (better) | −36.9% |
| Profitability | ||
| Gross margin | 78.7% (better) | 61.9% |
| Operating margin | −101210% | −51515% (better) |
| Net margin | −106283% | −40439% (better) |
| FCF margin | −33047% (better) | −39264% |
| Return on equity | −196% | −75.7% (better) |
| Return on invested capital | −180% (better) | −388% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −18.8× | – |
| Current ratio | 0.13 | 9.97 (better) |
| Altman Z-score | −8.23 | – |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 3.4% | 0.00% |
| Held by insiders | – | 63.6% |
| Insider net buying, 12 months | −$469K | – |
| Short interest, % of float | – | 3.2% |
Go deeper
- AIMD stock overview
- AIMD income statement
- AIMD valuation and score
- VRAX stock overview
- VRAX income statement
- VRAX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.